Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
Latest Information Update: 04 Jun 2025
At a glance
- Drugs DK 2 10 (Primary) ; Capecitabine; Carboplatin; Fluorouracil; Nivolumab; Oxaliplatin; Paclitaxel; Pembrolizumab
- Indications Adenocarcinoma; Colorectal cancer; Ductal carcinoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms DEKA-1
- Sponsors Deka Biosciences
Most Recent Events
- 29 May 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Jul 2025.
- 29 May 2025 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2025 Planned End Date changed from 1 Feb 2025 to 1 Oct 2025.